Table 2 Association between SMARCA4 and SMARCA2 mRNA expression and clinicopathological factors in the renal clear cell carcinoma dataset from TCGA.

From: High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer

Factor SMARCA4 expression SMARCA2 expression
High expressiona n = 54 Lower expressionb n = 479 P value High expressiona n = 54 Lower expressionb n = 479 P value
Age 58.48 ± 11.0 60.84 ± 12.2 0.15c 57.6 60.9 0.06c
Gender    0.037 d    0.99d
 Male 28 (51.9%) 317 (66.2%)   35 (64.8%) 310 (64.7%)  
 Female 26 (48.1%) 162 (33.8%)   19 (35.2%) 169 (35.3%)  
Tumor stage    0.16d    0.028 d
 T1 + T2 30 (55.6%) 312 (65.1%)   42 (75.9%) 300 (62.6%)  
 T3 + T4 24 (44.4%) 167 (34.9%)   12 (24.1%) 179 (37.4%)  
Tumor stage (S)    0.076d    0.019 d
 SI + SII 27 (50.0%) 297 (62.4%)   41 (75.9%) 283 (59.5%)  
 SIII + SIV 27 (50.0%) 179 (37.6%)   13 (24.1%) 193 (40.5%)  
Lymph node metastasis    0.035 d    0.06d
 N0 30 (85.7%) 209 (95.0%)   26 (92.9%) 213 (93.8%)  
 N1 5 (14.3%) 11 (5.0%)   2 (7.1%) 14 (6.2%)  
Metastasis Stage Code    0.0009 d    0.24d
 M0 34 (68.0%) 387 (86.0%)   45 (86.5%) 376 (83.9%)  
 M1 16 (32.0%) 63 (14.0%)   7 (13.5%) 72 (16.1%)  
Histologic grade    0.043 d    0.008 d
 G1 + G2 17 (32.7%) 224 (47.5%)   33 (63.5%) 209 (44.2%)  
 G3 + G4 35 (66.0%) 248 (52.5%)   19 (36.5%) 264 (55.8%)  
  1. aDecile of the tumor population with higher levels of SMARCA4 or SMARCA2 mRNA.
  2. bRest of the tumors not included in the high expression decile.
  3. cStudent’s t-test.
  4. dChi-square test. Significant P values (P ≤ 0.05) are depicted in bold.